CTLA4 and melanoma: On the other hand, poly(lactide-co-glycolide) vaccines combined with anti-CTLA-4 checkpoint inhibitors demonstrated promising results, regressing B16 melanoma tumors in mice and increasing survival rates by 75% (128).